154 related articles for article (PubMed ID: 33191745)
1. Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy.
Liu Y; Eckenrode JM; Zhang Y; Zhang J; Hayden RC; Kyomuhangi A; Ponomareva LV; Cui Z; Rohr J; Tsodikov OV; Van Lanen SG; Shaaban KA; Leggas M; Thorson JS
J Med Chem; 2020 Nov; 63(22):14067-14086. PubMed ID: 33191745
[TBL] [Abstract][Full Text] [Related]
2. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma.
Flores G; Everett JH; Boguslawski EA; Oswald BM; Madaj ZB; Beddows I; Dikalov S; Adams M; Klumpp-Thomas CA; Kitchen-Goosen SM; Martin SE; Caplen NJ; Helman LJ; Grohar PJ
Mol Cancer Ther; 2020 May; 19(5):1183-1196. PubMed ID: 32127464
[TBL] [Abstract][Full Text] [Related]
3. Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers.
Mitra P; Eckenrode JM; Mandal A; Jha AK; Salem SM; Leggas M; Rohr J
J Med Chem; 2018 Sep; 61(17):8001-8016. PubMed ID: 30114371
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.
Grohar PJ; Glod J; Peer CJ; Sissung TM; Arnaldez FI; Long L; Figg WD; Whitcomb P; Helman LJ; Widemann BC
Cancer Chemother Pharmacol; 2017 Sep; 80(3):645-652. PubMed ID: 28735378
[TBL] [Abstract][Full Text] [Related]
5. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
6. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
7. Mithramycin A Radiosensitizes EWS:Fli1
Lin MY; Damron TA; Oest ME; Horton JA
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1454-1471. PubMed ID: 33373655
[TBL] [Abstract][Full Text] [Related]
8. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
9. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
10. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
11. The antitumor antibiotic mithramycin: new advanced approaches in modification and production.
Kormanec J; Novakova R; Csolleiova D; Feckova L; Rezuchova B; Sevcikova B; Homerova D
Appl Microbiol Biotechnol; 2020 Sep; 104(18):7701-7721. PubMed ID: 32686008
[TBL] [Abstract][Full Text] [Related]
12. EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Issaq SH; Mendoza A; Kidner R; Rosales TI; Duveau DY; Heske CM; Rohde JM; Boxer MB; Thomas CJ; DeBerardinis RJ; Helman LJ
Mol Cancer Ther; 2020 Jul; 19(7):1520-1529. PubMed ID: 32371575
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kang M; Reynolds CP; Billups CA; Favours E; Payne-Turner D; Tucker C; Smith MA
Pediatr Blood Cancer; 2010 Dec; 55(6):1224-6. PubMed ID: 20979180
[TBL] [Abstract][Full Text] [Related]
14. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
[TBL] [Abstract][Full Text] [Related]
15. Allosteric interference in oncogenic FLI1 and ERG transactions by mithramycins.
Hou C; Mandal A; Rohr J; Tsodikov OV
Structure; 2021 May; 29(5):404-412.e4. PubMed ID: 33275876
[TBL] [Abstract][Full Text] [Related]
16. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer.
Malek A; Núñez LE; Magistri M; Brambilla L; Jovic S; Carbone GM; Morís F; Catapano CV
PLoS One; 2012; 7(4):e35130. PubMed ID: 22545098
[TBL] [Abstract][Full Text] [Related]
18. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
19. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
20. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.
Pedersen EA; Menon R; Bailey KM; Thomas DG; Van Noord RA; Tran J; Wang H; Qu PP; Hoering A; Fearon ER; Chugh R; Lawlor ER
Cancer Res; 2016 Sep; 76(17):5040-53. PubMed ID: 27364557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]